哈希游戏
热门标签

免费足球贴士:Big halal medicine market for Pharmaniaga

时间:1周前   阅读:2   评论:2

Telegram游戏群www.tel8.vip)是一个Telegram群组分享平台。Telegram游戏群包括Telegram群成员导出、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。Telegram游戏群为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

MIDF Research said while it was positive on the endeavour, the feasibility of the partnership and strategies would not be visible until at least next year.

PETALING JAYA: Pharmaniaga Bhd’s new venture involving the production of halal medicines is expected to bear fruit earliest, by next year.

MIDF Research said while it was positive on the endeavour, the feasibility of the partnership and strategies would not be visible until at least next year.

“We make no changes to our earnings estimates for financial year 2022 (FY22) to FY23, thus maintaining our target price at 91 sen for Pharmaniaga.

“The development of the halal anti-coagulant would not be finalised until approval by the National Pharmaceutical Regulatory Agency by 2024, with the risk of a fallout still an immediate possibility,” it said in a report.

Pharmaniaga said last week that it would commercialise Malaysia’s halal ovine (sheep and goat) anti-coagulant (blood clot thinner) drug in Malaysia by 2024.

The venture is a collaboration with China’s Ronnsi Pharma Co Ltd.

MIDF in its report noted that Covid-19 had added to the need for anti-coagulants in a bid to prevent severe complications from thromboembolism.

“Additionally, ischaemic heart diseases had seen a significant increase by 24% from 2015 to 2020, adding to the need for anti-blood clot agent to ease heart surgery and minimise complication,” it said.

,

免费足球贴士www.hgbbs.vip)是国内最权威的足球赛事报道、预测平台。免费提供赛事直播,免费足球贴士,免费足球推介,免费专家贴士,免费足球推荐,最专业的免费足球贴士网。

,

It also noted that the anti-coagulant market is expected to reach eight million dosages by 2026. There are big opportunities in halal market, it said.

“Anti-coagulants are used for invasive surgeries, as well as in preventive treatment for cardiovascular and cerebrovascular diseases.

“As most anti-coagulants in the market currently is derived from swine, the demand for halal anti-coagulants is expected to rise.”

It said the venture will position Pharmaniaga as the exclusive registration holder, distributor and manufacturer, with Ronnsi as the patent owner and developer.

It will also contribute to Malaysia’s potential as the first distributor and manufacturer of halal blood anti-coagulants, MIDF said.

In its report, MIDF pointed out that Ronnsi was founded in 2012 and is a pharma company focusing on complex drug research and development, with its main products being Heparin, Enoxaparin and Dalteparin salts.

“Ronnsi is the first developer of non-porcine-based enoxaparin, which has passed all approvals and is currently commercialised globally as an ovine-based anti-coagulant.

“Through this expertise, the group has collaborated with various international companies including from Indonesia, Pakistan, the United States and Italy.”

Still, there are threats to this partnership including pricing pressures and increased competition, MIDF said in its risk analysis.

上一篇:usdt官网接口(www.trc20.vip):Globetronics to diversify

下一篇:皇冠最新登陆网址(www.hg108.vip):Insight - Funds are turning sour on gold, unexpectedly

网友评论

  • 2022-09-06 00:39:20

    END-JUNE is when business owners get into a frenzy, rushing to file their tax returns to avoid getting compounded by the Internal Revenue Service for late submission. This has proved to be problematic for business owners who are not technology-savvy as the IRS has discontinued face-to-face customer guidance for e-filing. Many traditional SME business owners still prefer over-the-counter service submission and the assistance of IRS officers is not something that can be done away with at this point in time.九年义务教育都没你秀~

  • 2022-09-18 00:41:37

      随着老将邵婷、孙梦然相继离开球队,在补充了包括杨舒予在内的多位年轻队员后,中国女篮也正处于新老交替阶段。很内涵